Pharmacological Interventions in Autism: Theoretical and Practical Issues

Journal of Clinical Child and Adolescent Psychology

Volumn 30, Issue 1, 2001, Pages 80-87

  Volkmar, Fred R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AUTISM; BIOLOGICAL MODEL; CHILD; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RESEARCH; REVIEW; TREATMENT OUTCOME;

AUTISTIC DISORDER; CHILD; HUMANS; MODELS, BIOLOGICAL; NEUROTRANSMITTER AGENTS; RESEARCH; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0035287840     PISSN: 15374416     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15374424JCCP3001_9     Document Type: Article

References (61)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Anderson, G. M., & Hoshino, Y. (1997). Neurochemical studies of autism. In D. J. Cohen & F. R. Volkmar (Eds.), Handbook of autism and pervasive developmental disorders (2nd ed., pp. 325-343). New York: Wiley.
3. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195-1202.
4. Angold, A, Costello, E. J., & Erkanli, A. (1999). Comorbidity. Journal of Child Psychology and Psychiatry, 40, 57-88.
5. Bachevalier, J. (1996). Brief report: Medial temporal lobe and autism: A putative animal model in primates. Journal of Autism & Developmental Disorders, 26, 217-220.
6. Brodkin, E. S., McDougle, C. J., Naylor, S. T., Cohen, D. J., & Price, L. H. (1997). Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Child and Adolescent Psychopharmacology, 7, 109-121.
7. Campbell, M., Adams, P., Perry, R., Spencer, E. K., & Overall, J. E. (1988). Tardive and withdrawal dyskinesia in autistic children: A prospective study. Psychopharmacology Bulletin, 24, 251-255.
8. Campbell, M., Adams, P., Small, A. M., Curren, E. L., Overall, J. E., Anderson, L. T., Lynch, N., & Perry, R. (1988). Efficacy and safety of fenfluramine in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 434-439.
9. Campbell, M., Anderson, L. T., & Meier, M. (1979). A comparison of haloperidol, behavior therapy, and their interaction in autistic children [proceedings]. Psychopharmacol Bulletin, 15, 84-86.
10. Campbell, M., Anderson, L., Meier, M., Cohen, I., Small, A., Samit, C., & Sachar, E. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 17, 640-655.
11. Campbell, M., Anderson, L. T., Small, A. M., Adams, P., & et al. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child & Adolescent Psychiatry, 32(6), 1283-1291.
12. Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., & Koh, C. (1972). Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children. Journal of Autism and Child Schizophrenia, 2, 343-358.
13. Campbell, M., Kafantaris, V., Malone, R. P., Kowalik, S. C., & Locascio, J. J. (1991). Diagnostic and assessment issues related to pharmacotherapy for children and adolescents with autism. Behavior Modification, 15, 326-354.
14. Campbell, M., Overall, J. E., Small, A. M., Sokol, M. S., Spencer, E. K., Adams, P., Foltz, R. L., Monti, K. M., Perry, R., Nobler, M., & et al. (1989). Naltrexone in autistic children: An acute open dose range tolerance trial. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 200-206.
15. Campbell, M., Schopler, E., Cueva, J. E., & Hallin, A. (1996). Treatment of autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 134-143.
16. Cohen, D. J., Shaywitz, B. A., Johnson, W. T., & Bowers, M., Jr. (1974). Biogenic amines in autistic and atypical children. Cerebrospinal fluid measures of homovanillic acid and 5-hydroxyindoleacetic acid. Archives of General Psychiatry, 31(6), 845-853.
17. Cohen, D. J., Young, J. G., & Roth, J. A. (1977). Platelet monoamine oxidase in early childhood autism. Archives of General Psychiatry, 34, 534-537.
18. Colette, J. W. (1978). Speculation on similarities between autism and opiate addiction. Journal of Autism and Child Schizophrenia, 8, 477-479.
19. Cook, E. H. (1990). Autism: Review of neurochemical investigation. Synapse, 6, 292-308.
20. Cook, E. H., Jr., Rowlett, R., Jaselskis, C., & Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739-745.
21. Cook, E. H., Jr., Perry, B. D., Dawson, G., Wainwright, M. S., & Leventhal, B.L. (1993). Receptor Inhibition by immunoglobulins: Specific inhibition by autistic children, their relatives, and control subjects. Journal of Autism & Developmental Disorders, 23, 67-78.
22. Corbett, R., Hartman, H., Kerman, L. L., Woods, A. T., Strupczewski, J. T., Helsley, G. Conway, P. C., & Dunn, R. W. (1993). Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacology Biochemistry and Behavior, 45, 9-17.
23. Duker, P. C., Welles, K., Seys, D., Rensen, H., Vis, A., & van den Berg, G. (1991). Brief report: effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistictype mentally handicapped individuals. Journal of Autism & Developmental Disorders, 21, 355-363.
24. Ekman, G., Miranda-Linne, F., Gillberg, C., Garle, M., & Wetterberg, L. (1989). Fenfluramine treatment of twenty children with autism. Journal of Autism & Developmental Disorders, 19, 511-532.
25. Freeman, B. J., Ritvo, E. R., Yokota, A., & Ritvo, A. (1986). A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American Academy of Child and Adolescent Psychiatry, 25, 130-136.
26. Geller, E., Ritvo, E. R., Freeman, B. J., & Yuwiler, A. (1982). Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. New England Journal of Medicine, 307, 165-169.
27. Gillberg, C., Svennerholm, L., & Hamilton-Hellberg, C. (1983). Childhood psychosis and monoamine metabolites in spinal fluid. Journal of Autism & Developmental Disorders, 13, 383-396.
28. Geller, E. L., Young, J. G., Breakefield, X. O., Carbonari, C., Braverman, M., & Cohen, D. J. (1980). Monoamine oxidase and catechol-O-methyltransferase activities in cultured fibroblasts and blood cells from children with autism and the Gilles de la Tourette syndrome. Psychiatry Research, 2, 187-197.
29. Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447.
30. Howlin, P., & Goode, S. (1998). Outcome in autism and related conditions. In F. R. Volkmar (Ed.), Autism and pervasive developmental disorders (pp. 209-241). Cambridge, England: Cambridge University Press.
31. Iverson, S. D., & Iverson, L. L. (1981). Behavioral pharmacology (2nd Ed.). New York: Oxford University Press.
32. Leboyer, M., Bouvard, M. P., Launay, J. -M., Tabuteau, F., Waller, D., Dugas, M., Kerdelhue, B., Lensing, P., & Panksepp, J. (1992). A double-blind study of naltrexone in infantile autism. Journal of Autism & Developmental Disorders, 22(2), 309-319.
33. Le Couteur, A., Trygstad, O., Evered, C., Gillberg, C., & Rutter, M. (1988). Infantile autism and urinary excretion of peptides and protein-associated peptide complexes. Journal of Autism & Developmental Disorders, 18, 181-190.
34. Leventhal, B. L., Cook, E. H., Morford, M., Ravitz, A. J., Heller, W., & Freedman, D. X. (1993). Clinical and neurochemical effects of fenfluramine in children with autism. Journal of Neuropsychiatry & Clinical Neurosciences, 5, 307-315.
35. Lord, C. (1995). Follow-up of two-year-olds referred for possible autism. Journal of Child Psychology and Psychiatry, 36, 1365-1382.
36. Lord, C. (1996). Follow-up of two-year-olds referred for possible autism. Journal of Child Psychology and Psychiatry, 36, 1065-1076.
37. Lord, C. (1997). Diagnostic instruments in autism spectrum disorders. In D. J. Cohen & F. R. Volkmar (Eds.), Handbook of autism and pervasive developmental disorders (2nd ed., pp. 460-483). New York: Wiley.
38. McDougle, C. J. (1998). Psychopharmacology. In F. R. Volkmar (Ed.), Autism and pervasive developmental disorders (pp. 169-194). Cambridge, England: Cambridge University Press.
39. McDougle, C. J., Naylor, S. T., Volkmar, F. R., Cohen, D. J., Heninger, G. R., & Price, L. H. (1994). A double-blind, placebo-controlled investigation of fluvoxamine in adults with autism. Society for Neuroscience Abstracts, 20(1), 396.
40. Mesibov, G., & Handlan, S. (1997). Adolescents and adults with autism. In D. J. Cohen & F. R. Volkmar (Eds.), Handbook of autism and pervasive developmental disorders (2nd ed., pp. 309-324). New York: Wiley.
41. Narayan, M., Anderson, G. M., & Srinath, S. (1993). CSF HVA in autism (in reply). Biological Psychiatry, 34, 746-747.
42. Naruse, H., Nagahata, M., Nakane, Y., Shirahashi, K., Takesada, M., & Yamazaki, K. (1982). A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design. Acta Paedopsychiatrica, 48, 173-184.
43. Panksepp, J. (1979). A neurochemical theory of autism. Trends in Neuroscience, 2, 174-177.
44. Perry, R., Campbell, M., Adams, P., Lynch, N., Spencer, E. K., Curren, E. L., & Overall, J. E. (1989). Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. Journal of the American Acadamy of Child & Adolescent Psychiatry, 28, 87-92.
45. Ratey, J. J., Bemporad, J., Sorgi, P., Bick, P., Polakoff, S., Driscoll, G. O., & Mikkelsen, E. (1987a). Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. Journal of Autism & Developmental Disorders, 17, 439-446.
46. Ratey, J. J., Mikkelsen, E., & Chmielinski, H. E. (1989). Buspirone therapy for maladaptive behaviors and anxiety in developmentally disabled persons. Journal of Clinical Psychiatry, 50, 382-384.
47. Ratey, J. J., Mikkelsen, E., Sorgi, P., Zuckerman, H. S., Polakoff, S., Bemporad, J., Bick, P., & Kadish, W. (1987b). Autism: The treatment of aggressive behaviors. Journal of Clinical Psychopharmacology, 7, 35-41.
48. Realmuto, G. M., August, G. J., & Garfinkel, B. D. (1989). Clinical effect of buspirone in autistic children. Journal of Clinical Psychopharmacology, 9, 122-125.
49. Ritvo, E. R., Freeman, B. J., Geller, E., & Yuwiler, A. (1983). Effects of fenfluramine on 14 outpatients with the syndrome of autism. Jouyrnal of the American Academy of Child Psychiatry, 22, 549-558.
50. Rutter, M., Bailey, A., Simonoff, E., & Pickles, A. (1997) Genetic influences and autism. In D. Cohen & F. Volkmar (Eds.), Handbook of autism and pervasive developmental disorders (2nd ed., pp. 370-378). New York: Wiley.
51. Rutter, M., Silberg, J., O'Connor, T., & Simonoff, E. (1999). Genetics and child psychiatry: I. advances in quantitative and molecular genetics. Journal of Child and Psychological Psychiatry, 40, 3-18.
52. Sandman, C. A. (1991). The opiate hypothesis in autism and self-injury. Journal of Child & Adolescent Psychopharmacology, 1, 237-248.
53. Sandman, C. A. (1992). Various endogenous opioids and autistic behavior: A response to Gillberg. Journal of Autism & Developmental Disorders, 22, 132-133.
54. Schain, R. J., & Freedman, D. X. (1961). Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. Journal of Pediatrics, 58, 315-320.
55. Sherman, J., Factor, D. C., Swinson, R., & Darjes, R. W. (1989). The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. Journal of Autism & Developmental Disorders, 19, 533-543.
56. Todd, R. D., & Ciaranello, R. D. (1985). Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proceedings of the National Academy of Sciences USA, 82, 612-616.
57. Volkmar, F. R., & Lord, C. (1998). Diagnosis and definition of autism and other pervasive developmental disorders. In F. R.Volkmar (Ed.), Autism and pervasive developmental disorders (pp. 1-31). Cambridge, England: Cambridge University Press.
58. Volkmar, F. R., Klin, A., & Cohen, D. J. (1997). Diagnosis and classification of autism and related conditions: Consensus and issues. In D. J. Cohen & F. R. Volkmar (Eds.), Handbook of autism and pervasive developmental disorders (2nd ed., pp. 5-40). New York: Wiley.
59. Waterhouse, L., & Fein, D. (1998). Autism and the evolution of human social skills. In F. R. Volkmar (Ed.), Autism and pervasive developmental disorders (pp. 242-267). Cambridge, England: Cambridge University Press.
60. Willemsen-Swinkels, S. H., Buitelaar, J. K., Nijhof, G. J., & van England, H. (1995). Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Archives of General Psychiatry, 52, 766-773.
61. World Health Organization. (1994). Diagnostic criteria for research (10th ed.). Geneva: Author.